The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 15, 2018

Filed:

Jul. 10, 2013
Applicants:

Dana-farber Cancer Institute, Inc., Boston, MA (US);

The General Hospital Corporation, Boston, MA (US);

Inventors:

Kenneth C. Anderson, Wellesley, MA (US);

Teru Hideshima, Brookline, MA (US);

Ralph Mazitschek, Belmont, MA (US);

Gullu Gorgun, Chestnut Hill, MA (US);

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07C 223/06 (2006.01); A61K 45/06 (2006.01); A61K 31/136 (2006.01); A61K 31/15 (2006.01); A61K 31/164 (2006.01); A61K 31/165 (2006.01); A61K 31/216 (2006.01); A61K 31/395 (2006.01); A61K 31/4166 (2006.01); A61K 31/445 (2006.01); A61K 31/655 (2006.01); A61K 31/69 (2006.01); C07D 233/80 (2006.01); C07D 211/62 (2006.01); C07C 251/48 (2006.01); C07C 251/86 (2006.01);
U.S. Cl.
CPC ...
C07C 223/06 (2013.01); A61K 31/136 (2013.01); A61K 31/15 (2013.01); A61K 31/164 (2013.01); A61K 31/165 (2013.01); A61K 31/216 (2013.01); A61K 31/395 (2013.01); A61K 31/4166 (2013.01); A61K 31/445 (2013.01); A61K 31/655 (2013.01); A61K 31/69 (2013.01); A61K 45/06 (2013.01); C07C 251/48 (2013.01); C07C 251/86 (2013.01); C07D 211/62 (2013.01); C07D 233/80 (2013.01);
Abstract

The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, tautomers, stereoisomers, solvates, hydrates, polymorphs, and compositions thereof. Also provided are methods and kits involving the inventive compounds for treating proliferative diseases (e.g., cancers (e.g., breast cancer, prostate cancer, lung cancer, and ovarian cancer), benign neoplasms, angiogenesis, inflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound of the invention may enhance the anti-tumor immune response by inhibiting or eliminating the immune suppression mediated by immune suppressor myeloid cells (MDSCs), inducing apoptosis, and/or inhibit or down-regulate proteins (e.g., epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), X-linked inhibitor of apoptosis protein (XIAP), and heat shock protein 90 (Hsp90)) in the subject.


Find Patent Forward Citations

Loading…